Ranibizumab(Lucentis®), an antibody fragment that inhibits all isoforms of VEGF-A, andAflibercept (Eylea®), a fusion protein designed to bind to VEGF-A, VEGF-B,and platelet growth factor, were both FDA approved for the treatment of AMD in 2007and 2011, respectively(16,17,18). This evidence concerns the gene VEGFA and age-related macular degeneration.